Perkins Capital Management Inc. Acquires 563,490 Shares of TELA Bio, Inc. $TELA

Posted by Geri Gentry on May 13th, 2026

Perkins Capital Management Inc. raised its holdings in TELA Bio, Inc. (NASDAQ:TELA – Free Report) by 67.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,397,418 shares of the company’s stock after acquiring an additional 563,490 shares during the quarter. TELA Bio makes up about 1.3% of Perkins Capital Management Inc.’s portfolio, making the stock its 23rd largest holding. Perkins Capital Management Inc. owned about 3.46% of TELA Bio worth $1,649,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Citadel Advisors LLC raised its position in TELA Bio by 161.3% during the 3rd quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after purchasing an additional 21,781 shares during the last quarter. Susquehanna International Group LLP increased its stake in shares of TELA Bio by 551.2% in the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock valued at $128,000 after buying an additional 72,594 shares during the period. Embree Financial Group increased its stake in shares of TELA Bio by 695.1% in the fourth quarter. Embree Financial Group now owns 111,318 shares of the company’s stock valued at $131,000 after buying an additional 97,318 shares during the period. Finally, GSA Capital Partners LLP raised its position in shares of TELA Bio by 106.7% during the third quarter. GSA Capital Partners LLP now owns 105,809 shares of the company’s stock worth $158,000 after acquiring an additional 54,613 shares during the last quarter. Institutional investors and hedge funds own 94.35% of the company’s stock.

Analyst Ratings Changes

TELA has been the subject of a number of recent analyst reports. Lake Street Capital decreased their target price on shares of TELA Bio from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th. Citizens Jmp cut their price target on shares of TELA Bio from $5.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Friday, March 27th. Canaccord Genuity Group cut their target price on TELA Bio from $4.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, March 25th. Piper Sandler dropped their price target on TELA Bio from $1.25 to $1.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 25th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TELA Bio in a report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $2.20.

View Our Latest Report on TELA

TELA Bio Trading Up 5.1%

TELA opened at $1.02 on Wednesday. The firm has a market capitalization of $45.67 million, a PE ratio of -1.23 and a beta of 1.30. The company has a debt-to-equity ratio of 8.82, a current ratio of 4.20 and a quick ratio of 3.59. TELA Bio, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $2.20. The company’s 50-day moving average is $0.76 and its 200 day moving average is $0.96.

TELA Bio (NASDAQ:TELA – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.07). The company had revenue of $19.06 million for the quarter, compared to analysts’ expectations of $18.60 million. TELA Bio had a negative net margin of 48.37% and a negative return on equity of 433.58%. As a group, research analysts predict that TELA Bio, Inc. will post -0.57 earnings per share for the current fiscal year.

TELA Bio Profile

(Free Report)

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.